Newsfeeds - Spark Newswire

1 minute read

Piper Sandler Initiates Coverage On Chinook Therapeutics with Overweight Rating, Announces Price Target of $41

Today, 4:55 PM

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Chinook Therapeutics (NASDAQ:KDNY) with a Overweight rating and announces Price Target of $41.

KDNY

2 minute read

Earnings

Chinook Therapeutics Earnings Perspective: Return On Capital Employed

By Benzinga Insights

Today, 4:55 PM

Benzinga Pro data, Chinook Therapeutics (NASDAQ:KDNY) reported Q4 sales of $512 thousand. Earnings fell to a loss of…

KDNY

1 minute read

Analyst Views Multiple Opportunities For Chinook To Thrive In Emerging Renal Markets, Sees More Than 100% Upside

By Vandana Singh

Today, 4:55 PM

Guggenheim starts coverage on Chinook Therapeutics Inc (NASDAQ:KDNY) with a Buy rating and a $43 price target, being ‘bullish’ on the immunoglobulin…

KDNY

1 minute read

Analyst Ratings

Where Chinook Therapeutics Stands With Analysts

By Benzinga Insights

Today, 4:55 PM

Within the last quarter, Chinook Therapeutics (NASDAQ:KDNY) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

KDNY

2 minute read

Have A Look At William Blair’s Top Biotech Picks For 2023

By Vandana Singh

Today, 4:55 PM

William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period.

ALBO

5 minute read

Chinook Therapeutics Presents Updated Data From Atrasentan Phase 2 AFFINITY IgA Nephropathy Patient Cohort, Preclinical Atrasentan Research And Ongoing Clinical Trials At The American Society Of Nephrology Kidney Week 2022

By Benzinga Newsdesk

Today, 4:55 PM

Atrasentan was well-tolerated with no treatment-related serious adverse events (SAEs) Atrasentan demonstrated mean proteinuria reductions of 38.1% proteinuria at six weeks of treatment, 48.3% at

KDNY

6 minute read

88 Biggest Movers From Yesterday

By Lisa Levin

Today, 4:55 PM

Gainers The Very Good Food Company Inc. (NASDAQ: VGFC) shares jumped 118.2% to close at $0.2950 on Wednesday as the company announced it increased retail distribution across Canada with Loblaw Companies.

ADXN

3 minute read

The Daily Biotech Pulse: Third FDA Rejection For Verrica’s Skin Disease Drug, Assembly Bio Terminates Hepatitis B Virus Pact, Consistency Data For Valneva’s Chikungunya Vaccine

By Vandana Singh

Today, 4:55 PM

Here's a roundup of top developments in the biotech space over the last 24 hours.

ASMB

2 minute read

21 Stocks Moving in Wednesday’s Pre-Market Session

By Lisa Levin

Today, 4:55 PM

Gainers The Singing Machine Company, Inc. (NASDAQ: MICS) shares rose 47.3% to $4.05 in pre-market trading.

ADXN

1 minute read

Chinook Therapeutics Priced ~6.4M Share Offering @$14/Share

By Charles Gross

Today, 4:55 PM

Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced the pricing of its underwritten public offering of 6,428,572 shares of its common stock at a price to the public of $14.00 per share.

KDNY